Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SH) has announced that its subsidiary, Guangzhou Baiyunshan Chenliji Pharmaceutical Factory Co., Ltd. (referred to as "Chenliji Pharmaceutical Factory"), recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration regarding the addition of new indications for Shujin Jianyao Pill.

The approval permits the product to conduct clinical trials for the treatment of lumbar disc herniation with liver-kidney deficiency syndrome and wind-dampness obstruction syndrome.